Brainstorm Cell Therapeutics (NASDAQ:BCLI) Upgraded at StockNews.com

StockNews.com upgraded shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) from a sell rating to a hold rating in a research report released on Monday morning.

Brainstorm Cell Therapeutics Price Performance

Shares of BCLI opened at $2.13 on Monday. The stock has a 50-day moving average of $1.85 and a 200-day moving average of $3.09. Brainstorm Cell Therapeutics has a one year low of $1.05 and a one year high of $11.89. The company has a market cap of $12.14 million, a PE ratio of -0.44 and a beta of 0.29.

Institutional Trading of Brainstorm Cell Therapeutics

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Armistice Capital LLC acquired a new position in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned about 11.30% of Brainstorm Cell Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 14.33% of the company’s stock.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.